A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

Stopped Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2.

Conditions

• Acute Myeloid Leukemia

Interventions

• DRUG: Idasanutlin
• DRUG: Cytarabine
• DRUG: Daunorubicin
• PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)

Sponsor

Hoffmann-La Roche